BridgeMD
Tests treatment safety and results for Epidermolysis Bullosa Simplex
Official title A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
ClinicalTrials.gov ID: NCT06136403
What this study is testing
What is deucravacitinib?
deucravacitinib is an investigational medicine, being studied as a potential treatment for epidermolysis bullosa simplex.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Subject has congenital skin fragility with skin and/or mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS...
- Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS \> 50/128.
- Subject agrees not to use any topical therapies other than the investigator approved.
You likely can't join if
- people with another form of ICI ie Netherton syndrome, Kid syndrome etc.
- Infectious/Immune-related Exclusions
- Medical History and Concurrent Diseases
The study team makes the final eligibility decision.
Where it's taking place
- Nice, CHU de NICE, France
- Paris, France, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nice, CHU de NICE, France; Paris, France, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.